Immix Biopharma, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Leadership changes can affect how a company operates, though management said this won't hurt the business.
Shareholders voted to keep the company's leadership team and choose who checks the financial records.
New money helps companies fund operations and research; higher share count can dilute existing shareholders.
Legal document explains the terms of the new shares being sold to the public.
Strong clinical trial results can signal a medicine might work, potentially making the company more valuable.
Quarterly reports show how much money the company made or lost and its financial health.
Trial completion milestone suggests the company is progressing toward proving if its medicine works.
Stocky reads Immix Biopharma, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Immix Biopharma, Inc.'s most recent tracked filing was a 8-K on 20 Jul 2026: Richard Graydon terminated from company July 17.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.